Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.
Splitting does smooth the curve, and that is the problem. With a one-week half-life the weekly curve is already fairly flat — peak-to-trough is modest — so splitting buys very little smoothing while doubling the number of punctures, the number of arithmetic opportunities and the number of chances to lose material to dead space. The people who report a real benefit are usually those whose difficulty is a day-one side effect, which is a peak problem and is the one case where splitting genuinely helps.
Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.
What I am trying to establish is what the pharmacokinetic argument against splitting a weekly dose actually is, since intuitively it should smooth the curve. Numbers rather than impressions, if you have them.
Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.